

KFIN/CERT13(3)/MAR/2026

Date : April 21, 2026

Mr. Ajay Nadkarni
M/s. GlaxoSmithKline Pharmaceuticals Limited
Dr. Annie Besant Road
Worli, Mumbai-400025.

Sub : Investor Grievance Certificate for the quarter ended March 31, 2026.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended March 31, 2026.

Description of Complaint	Opening Balance as on 01.01.2026	Received during the Period 01.01.2026 to 31.03.2026	Attended/Resolved during the Period 01.01.2026 to 31.03.2026	Pending as on 31.03.2026
Non-receipt of Dividend	NIL	NIL	NIL	NIL
Non-receipt of Annual reports	NIL	NIL	NIL	NIL
Non receipt of shares	NIL	NIL	NIL	NIL
SEBI	02	14	08	08
Stock Exchange	NIL	NIL	NIL	NIL
ODR	NIL	02	02	NIL
Total	02	16	10	08

This is for your information and record.

Thanking you,

Yours faithfully
For KFin Technologies Limited



Dnyanesh Gharote
Vice President

KFin Technologies Limited

(Formerly known as KFin Technologies Private Limited)

Registered & Corporate Office:

Selenium Building, Tower-B, Plot No- 31 & 32, Financial District, Nanakramguda,
Serilingampally, Hyderabad, Rangareddi, Telangana, India, 500032.

CIN: L72400TG2017PLC117649